Citations

Showing 10 of 108104 citations.

Propeptide glycosylation and galectin‐3 binding decrease proteolytic activation of human proMMP‐9/progelatinase B
Boon, Lise , Ugarte-Berzal, Estefanía , Martens, Erik , Vandooren, Jennifer , Rybakin, Vasily , Colau, Didier , Bruggen, Pierre van der , Stöcker, Walter , Becker‐Pauly, Christoph , Jaeken, Jaak , Proost, Paul , Opdenakker, Ghislain , Proost, Paul , Opdenakker, Ghislain , Gordón‐Alonso, Mónica , Witters, Peter , Morava, Éva

Mayo Clinic

The FEBS Journal | November 13, 2018 | Volume: 286 | Issue: 5 | Pages: 930-945

10.1111/febs.14698 | PMID 30422384 Get It

Matrix metalloproteinases (MMPs) are secreted as proenzymes, containing propeptides that interact with the catalytic zinc, thereby controlling MMP activation. The MMP‐9 propeptide is unique in the MMP family because of its post‐translational modification with an N‐linked oligosaccharide. ProMMP‐9 activation by MMP‐3 occurs stepwise by cleavage of the propeptide in an aminoterminal (pro‐AT) and carboxyterminal (pro‐CT) peptide. We chemically synthesized aglycosyl pro‐AT and pro‐CT and purified recombinant glycosylated pro‐ATSf−9. First, we report new cleavage sites in the MMP‐9 propeptide by MMP‐3 and neutrophil elastase. Additionally, we demonstrated with the use of western blot analysis a higher resistance of glycosylated versus aglycosyl pro‐AT against proteolysis by MMP‐3, MMP‐9, meprin α, neutrophil elastase and by protease‐rich synovial fluids from rheumatoid arthritis patients. Moreover, we investigated the effect of glycosylation on proteolytic activation of human proMMP‐9 with the use of zymography and dye‐quenched gelatin cleavage analysis. Compared to recombinant Sf‐9 proMMP‐9 glycoforms, larger oligosaccharides of human neutrophil proMMP‐9 increased resistance against proteolytic activation. Additionally, proMMP‐9 from Congenital Disorder of Glycosylation patients, compared to healthy controls, showed a higher activation rate by MMP‐3. Finally, we demonstrated that glycan‐galectin‐3 interactions reduced proMMP‐9 activation. In conclusion, modification of MMP‐9 propeptide glycosylation is a fine‐tuning mechanism and co‐determines the specific activity of MMP‐9 in physiology and pathology.EnzymesMMP‐9 EC 3.4.24.35, MMP‐3 EC 3.4.24.17, meprin α EC 3.4.24.18, neutrophil elastase EC 3.4.21.37, trypsin EC 3.4.21.4 and PNGase F EC 3.5.1.52.
Seventeen-Year Follow-up After Meniscal Repair With Concomitant Anterior Cruciate Ligament Reconstruction in a Pediatric and Adolescent Population
Tagliero, Adam J. , Desai, Vishal , Kennedy, Nicholas I. , Levy, Bruce A. , Dahm, Diane L., Krych, Aaron J. , Desai, Vishal S. , Krych, Aaron J , Tagliero, Adam , Camp, Christopher L. , Stuart, Michael J.

Mayo Clinic

The American Journal of Sports Medicine | November 13, 2018 | Volume: 46 | Issue: 14 | Pages: 3361-3367

10.1177/0363546518803934 | PMID 30422671 Get It

Background: Studies have shown good and excellent clinical and radiographic results after meniscal repair. Limited published information exists on the long-term outcomes, however, especially in a pediatric and adolescent population. Purpose: To determine long-term results of meniscal repair and concomitant anterior cruciate ligament (ACL) reconstruction in a pediatric and adolescent population. Specifically, the aims were to determine the clinical success rate of meniscal repair with concomitant ACL reconstruction, compare results with midterm outcomes, and analyze risk factors for failure. Study Design: Case series; Level of evidence, 4. Methods: Cases of meniscal repair with concomitant ACL reconstruction between 1990 and 2005 were reviewed among patients aged ≤18 years. Patient demographics, injury history, and surgical details were recorded, and risk factors for failure were analyzed. Physical examination findings and clinical outcomes at latest available follow-up were collected. Subjective knee outcomes were compared with midterm results. Descriptive statistics and univariate analysis were used to evaluate the available data. Results: Forty-seven patients (30 females, 17 males) with a mean age of 16 years (SD, 1.37) and a mean follow-up of 16.6 years (SD, 3.57) were included in this study. Overall, 13 patients (28%) failed meniscal repair and required repeat surgery at the time of final follow-up. Of the 13 failures, 9 underwent a subsequent meniscectomy; 2, meniscectomy and revision ACL reconstruction; 1, meniscal repair and revision ACL reconstruction; and 1, meniscal repair and subsequent meniscectomy. Mean International Knee Documentation Committee scores improved from 47.9 preoperatively to 87.7 postoperatively ( P < .01), and the mean score at long-term follow-up (87.7) did not significantly differ from that at the midterm follow-up (88.5) at a mean 7.4 years ( P = .97). Mean Tegner Activity Scale scores improved from 1.9 preoperatively to 6.3 postoperatively ( P < .01) and decreased from 8.3 at preinjury to 6.3 at final long-term follow-up ( P < .01). Conclusion: In conclusion, the long-term overall clinical success rate (failure-free survival) was 72% for repair of pediatric and adolescent meniscal tears in the setting of concomitant ACL reconstruction. Patients reported excellent knee subjective outcome scores that remained favorable when compared with midterm follow-up.
Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS ® ) Society Recommendations: 2018
Gustafsson, Ulf , Scott, Michael J. , Hübner, Martin , Demartines, Nicolas , Rockall, Timothy , Young‐Fadok, Tonia M., Soop, Mattias , Boer, Hans D. de , Chang, George J. , Keßler, Hermann, Whang, Edward E. , Fawcett, William , Carli, F. , Lobo, Dileep N. , Rollins, Katie E. , Balfour, Angie , Ljungqvist, Olle , Demartines, N , Lobo, D N , Hübner, Martin , Nygren, Jonas , Francis, Nader Kamal , Hill, Andrew Graham , Urman, Richard D , Fichera, A., Grass, Fabian , Baldini, G., Riedel, Bernhard

Mayo Clinic

World Journal of Surgery | November 13, 2018 | Volume: 43 | Issue: 3 | Pages: 659-695

10.1007/s00268-018-4844-y | PMID 30426190 Get It

Abstract Background This is the fourth updated Enhanced Recovery After Surgery (ERAS ® ) Society guideline presenting a consensus for optimal perioperative care in colorectal surgery and providing graded recommendations for each ERAS item within the ERAS ® protocol. Methods A wide database search on English literature publications was performed. Studies on each item within the protocol were selected with particular attention paid to meta‐analyses, randomised controlled trials and large prospective cohorts and examined, reviewed and graded according to Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Results All recommendations on ERAS ® protocol items are based on best available evidence; good‐quality trials; meta‐analyses of good‐quality trials; or large cohort studies. The level of evidence for the use of each item is presented accordingly. Conclusions The evidence base and recommendation for items within the multimodal perioperative care pathway are presented by the ERAS ® Society in this comprehensive consensus review.
Timing of treatment of smoldering myeloma: delay until progression
Kumar, Shaji , Kumar, Shaji K

Mayo Clinic

Blood Advances | November 13, 2018 | Volume: 2 | Issue: 21 | Pages: 3050-3053

10.1182/bloodadvances.2018021238 | PMID 30425069 Get It

Abstract This article has a companion Point by Mateos and González-Calle.
Strontium‐substituted hydroxyapatite stimulates osteogenesis on poly(propylene fumarate) nanocomposite scaffolds
Li, Jingfeng , Liu, Xifeng , Park, Sungjo , Miller, A. Lee , Lu, Lichun , Miller, Alan Lee , Terzic, André

Mayo Clinic

Journal of Biomedical Materials Research Part A | November 13, 2018 | Volume: 107 | Issue: 3 | Pages: 631-642

10.1002/jbm.a.36579 | PMID 30422387 Get It

Abstract Incorporation of hydroxyapatite (HA) into polymer networks is a promising strategy to enhance the mechanical properties and osteoinductivity of the composite scaffolds for bone tissue engineering. In this study, we designed a group of nanocomposite scaffolds based on cross‐linkable poly(propylene fumarate) (PPF) and 30 wt % strontium‐hydroxyapatite (Sr‐HA) nanoparticles. Four different Sr contents [Sr:(Sr + Ca), molar ratio] in the Sr‐HA particles were studied: 0% (HA), 5% (Sr5‐HA), 10% (Sr10‐HA), and 20% (Sr20‐HA). Two‐dimensional (2D) disks were prepared using a thermal crosslinking method. The structure and surface morphology of different Sr‐HA and PPF/Sr‐HA composites were characterized using scanning electron microscopy (SEM), energy‐dispersive X‐ray spectroscopy (EDS), transmission electron microscopy (TEM), and atomic force microscopy (AFM). To detect cellular responses in vitro, MC3T3‐E1 cells were seeded and cultured on the different PPF/Sr‐HA composite disks. Cell morphology after 24 h and 5 days were imaged using Live/Dead live cell staining and SEM, respectively. Cell proliferation was quantified using an MTS assay at 1, 4, and 7 days. Osteogenic differentiation of the cells was examined by alkaline phosphatase (ALP) staining at 10 days and quantified using ALP activity and osteocalcin assays at 7, 14, and 21 days. The sizes of the HA, Sr5‐HA, Sr10‐HA, and Sr20‐HA particles were mainly between 10 × 20 nm and 10 × 250 nm, and these nanoparticles were dispersed or clustered in the composite scaffolds. in vitro cell studies showed that the PPF/Sr10‐HA scaffold was significantly better than the other three groups (PPF/HA, PPF/Sr5‐HA, and PPF/Sr20‐HA) in supporting MC3T3‐E1 cell adhesion, proliferation, and differentiation. PPF/Sr10‐HA may, therefore, serve as a promising scaffold material for bone tissue engineering. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 631–642, 2019.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Harrell, Maria I., Oza, Amit M. , Oaknin, Ana , Tinker, Anna V. , Helman, Elena , Radke, Marc R. , Say, Carmen , Vo, Lan-Thanh, Mann, Elaina, Isaacson, Jeffrey D., Maloney, Lara , O’Malley, David M. , Chambers, Setsuko K., Scott, Clare L. , Konecny, Gottfried E. , Giordano, Heidi, Harding, Thomas C., McNeish, Iain A. , Swisher, Elizabeth M. , Lin, Kevin K. , Kaufmann, Scott H , Brenton, James D , McNeish, Iain A , Swisher, Elizabeth M , Scott, Clare L , O'Malley, David M , Lin, Kevin , Ray-Coquard, Isabelle L. , Kaufmann, Scott H. , Coleman, Robert L. , Sun, James X. , Brenton, James D.

Mayo Clinic

Cancer Discovery | November 13, 2018 | Volume: 9 | Issue: 2 | Pages: 210-219

10.1158/2159-8290.cd-18-0715 | PMID 30425037 Get It

Abstract A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC), we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib. BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049). Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P &lt; 0.0001). To study acquired resistance, we sequenced 78 postprogression cfDNA, identifying eight additional patients with BRCA reversion mutations not found in pretreatment cfDNA. Significance: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment. Sequencing of cfDNA can detect multiple BRCA reversion mutations, highlighting the ability to capture multiclonal heterogeneity. This article is highlighted in the In This Issue feature, p. 151
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Hong, David S. , LoRusso, Patricia , Hamid, Omid , Jankú, Filip , Kittaneh, Muaiad , Catenacci, Daniel V.T. , Chan, Emily , Bekaii‐Saab, Tanios , Loberg, Robert D., Amore, Benny , Hwang, Yuying C., Tang, Rui , Ngarmchamnanrith, Gataree, Kwak, Eunice L., Hong, David S , Bekaii-Saab, Tanios S , Gadgeel, Shirish M.

Mayo Clinic

Clinical Cancer Research | November 13, 2018 | Volume: 25 | Issue: 8 | Pages: 2403-2413

10.1158/1078-0432.ccr-18-1341 | PMID 30425090 Get It

Abstract Purpose: This first-in-human, open-label phase I study evaluated AMG 337, an oral, highly selective small-molecule inhibitor of MET in advanced solid tumors. Patients and Methods: Patients enrolled into dose-escalation cohorts received AMG 337 up to 400 mg once daily or up to 250 mg twice daily, following a modified 3+3+3 design. Dose expansion was conducted in MET-amplified patients at the maximum tolerated dose (MTD). Primary endpoints included assessment of adverse events (AEs), establishment of the MTD, and pharmacokinetics; clinical response was a secondary endpoint. Results: The safety analysis set included 111 patients who received ≥1 dose of AMG 337. Thirteen patients had ≥1 AE qualifying as dose-limiting toxicity. The MTD was determined to be 300 mg once daily; the MTD for twice-daily dosing was not reached. Most frequent treatment-related AEs were headache (63%) and nausea (31%). Grade ≥3 treatment-related AEs occurred in 23 patients (21%), most commonly headache (n = 6) and fatigue (n = 5). Maximum plasma concentration occurred at 3.0 hours following 300-mg once-daily dosing, indicating AMG 337 absorption soon after treatment. Objective response rate was 9.9% (11/111; 95% CI, 5.1%–17.0%) in all patients and 29.6% (8/27; 95% CI, 13.8%–50.2%) in MET-amplified patients; median (range) duration of response was 202 (51–1,430+) days in all patients and 197 (64–1,430+) days in MET-amplified patients. Conclusions: Oral AMG 337 was tolerated with manageable toxicities, with an MTD and recommended phase II dose of 300 mg once daily. The promising response rate observed in patients with heavily pretreated MET-amplified tumors warrants further investigation. See related commentary by Ma, p. 2375
Advanced Treatment Planning
Wedenberg, Minna, Beltran, Chris , Mairani, Andrea , Alber, M., Beltran, Chris J

Mayo Clinic

Medical Physics | November 13, 2018 | Volume: 45 | Issue: 11 | Pages: No page available

10.1002/mp.12943 | PMID 30421811 Get It

Treatment planning for protons and heavier ions is adapting technologies originally developed for photon dose optimization, but also has to meet its particular challenges. Since the quality of the applied dose is more sensitive to geometric uncertainties, treatment plan robust optimization has a much more prominent role in particle therapy. This has led to specific planning tools, approaches, and research into new formulations of the robust optimization problems. Tools for solution space navigation and automatic planning are also being adapted to particle therapy. These challenges become even greater when detailed models of relative biological effectiveness ( RBE ) are included into dose optimization, as is required for heavier ions.
Sex‐specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials
Jankowski, Catherine M. , Wolfe, Pamela, Schmiege, Sarah J. , Mühlen, Denise von, Laughlin, Gail A., Bergstrom, Jaclyn , Bettencourt, Richele, Weiss, Edward P., Villareal, Dennis T. , Kohrt, Wendy M., Nair, K. Sreekumaran , Khosla, Sundeep , Jensen, Michael, Kritz‐Silverstein, Donna C.

Mayo Clinic

Clinical Endocrinology | November 13, 2018 | Volume: 90 | Issue: 2 | Pages: 293-300

10.1111/cen.13901 | PMID 30421439 Get It

SummaryObjectiveStudies of dehydroepiandrosterone (DHEA) therapy in older adults suggest sex‐specific effects on bone mineral density (BMD) and body composition, but the ability of a single study to reach this conclusion was limited. We evaluated the effects of DHEA on sex hormones, BMD, fat mass and fat‐free mass in older women and men enrolled in four similar clinical trials.DesignPooled analyses of data from four double‐blinded, randomized controlled trials.ParticipantsWomen (n = 295) and men (n = 290) aged 55 years or older who took DHEA or placebo tablet daily for 12 months.MeasurementsTwelve‐month changes in BMD, fat mass, fat‐free mass and serum DHEA sulphate (DHEAS), (17)estradiol, testosterone and insulin‐like growth factor‐1 (IGF‐1).ResultsWomen on DHEA had increases (mean ± SD; all P < 0.001 vs placebo) in DHEAS (231 ± 164 µg/dL), testosterone (18.6 ± 20.9 µg/dL), (17)estradiol (8.7 ± 11.0 pg/mL) and IGF‐1 (25.1 ± 52.3 ng/mL), and men had increases in DHEAS (269.0 ± 177 µg/dL; P < 0.01), (17)estradiol (4.8 ± 12.2 pg/m; P < 0.01) and IGF‐1 (6.3 ± 41.4 ng/mL; P < 0.05). Women on DHEA had increases in lumbar spine (1.0% ± 3.4%) and trochanter (0.5% ± 3.8%) BMD and maintained total hip BMD (0.0% ± 2.8%); men had no BMD benefit and a decrease in fat mass (−0.4 ± 2.6 kg; all P < 0.01 vs placebo).ConclusionsDehydroepiandrosterone therapy may be an effective approach for preserving bone and muscle mass in women. Key questions are (a) the extent to which longer duration DHEA can attenuate the loss of bone and muscle in women, and (b) whether DHEA has a more favourable benefit‐to‐risk profile for women than oestrogen therapy.